人和猴T淋巴细胞表面TRBC受体和E受体的比例研究

In 1985, rosette formation of human and macaque pan-T lymphocytes with tree shrew red blood cells (TRBC) (TRBC rosette) was first found by Ben K et al, showing different physico-chemical properties from that of rosette formation with sheep red blood cells (E-rosette). In order to approach the correlation between TRBC receptor, E receptor (CD2) and other differentiation antigens (CDs) on T lymphocytes, rosette inhibition assay and antigenic modulation or co-modulation were performed with monoclonal antibodies (McAbs) to CDs, and the distribution of TRBC receptor in other peripheral immunocytes, cell lines was also examined. TRBC rosette appeared in 88.8% of E rosette positive peripheral blood lymphocytes (E(+)-PBL) and in 4.16% of E(-)-PBL. TRBC receptor was also found on all T cell lines tested (CEM, H33 HJ-JA 1, Jurkat, MLA-144, Molt-3, Molt-4, Molt-4 clone 8, PEER) and some myeloid lines (U 937 and HL 60), but not on human granulocytes, B cell lines (Daudi, Raji and Reh) and myeloid line K 562. The modulation or co-modulation of CD 3, TCR, CD 5, CD 6 and CD 7 with McAbs OKT 3, T 108 (F 1), T 136 (F 101-15), T 149 (M-T 604) and T 152 (7 G 5) did not affect TRBC rosette formation of PBL. TRBC rosette of human and rhesus monkey PBL was not inhibited by T 11.1 McAb OKT 11 (CD 2 McAb), in contrast human and rhesus monkey E rosette formations were obviously blocked at inhibition rates of 77.9% and 49.3%, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)     

人和猴T淋巴细胞表面TRBC受体和E受体的比较研究

TRBC受体不同于已知的全T细胞表面分化抗原CD2,CD3/TCR复合物,CD5,CD6和CD7。CD2分子不参与TRBC玫瑰花结的形成,也不是介导E花结的唯一分子。至少有两个或两个以上蛋白质与TRBC玫瑰花结和E花结的形成有关,其中有的分子为E受体和TRBC受体所共有。因此,很可能有不同于CD2的分子参与了TRBC玫瑰花结的形成。     

单克隆抗体亲和层析技术

亲和层析技术中用常规抗血清作配体时,由于抗血清成份复杂、亲和力多样化,特异性强的制剂又不易得,因而此层析技术的应用受到限制.单克隆抗体(McAb)技术的建立,为亲和层析技术的应用带来了突破.因为McAb作为亲和层析技术中的配体有以下几个优点:(1)可以利用粗制抗原制备分泌单一抗体的杂交瘤细胞株,在体外或体内大量生产McAb;(2)由于McAb是针对单一抗原决定簇的,该决定簇是某一抗原物质所特有或是多种抗原物质所共有时,可没有任何交叉反应或有完全的交叉反应.     

氯喹啉对免疫反应影响的研究

1．氯喹啉在20—40毫克／千克,每天两次,应用10—12天时,对家兔形成溶血素的能力无抑制作用,在40毫克时,反而刺激抗体形成(P<0.01一0.05)。 2．氯喹啉在0．2—1毫克／只小白鼠,每天两次,应用11日时,对小白鼠形成溶血素能力无抑制作用。 3．平行进行的6一MP试验,家兔形成抗体的能力受到抑制,小白鼠则不复有影响。 4．氯喹啉对豚鼠过敏反应无防止发生的作用。 5．根据实验结果进行了氯喹啉疗效机制的探讨,并指出进一步研究时的几个途径。